TK inhibitors

Angsana will support a Phase 2 basket trial for a tyrosine kinase inhibitor that targets tumors harboring TRK, ROS1, and ALK fusions.

Ahead of a cost-effectiveness appraisal by UK's NICE, AstraZeneca is paying for EGFR mutation testing for non-small cell lung cancer patients to determine if they will benefit from treatment with Iressa. The genetic testing program is part of a patient access scheme the company has agreed to with the National Health Service to provide more granularity about the cost and value of the treatment.

The Chan Zuckerberg Initiative is investing in Cold Spring Harbor Laboratory's BioRxiv.

A study appearing in PLOS One finds that shortened consent forms don't affect clinical trial participants' understanding of the study.

The National Security Agency monitored signal intelligence for signs of "nefarious" genetic engineering projects, Gizmodo reports.

In Nature this week: barley genome sequenced, method for genotyping and phasing short tandem repeats, and more.